Literature DB >> 8095827

P-glycoproteins: mediators of multidrug resistance.

U A Germann1, I Pastan, M M Gottesman.   

Abstract

Multidrug resistance represents a major obstacle to successful chemotherapy of metastatic disease. Elevated levels in cancer cells of the product of the multidrug resistance gene, P-glycoprotein or the multidrug transporter, have been associated with the development of simultaneous resistance to a great variety of amphiphilic cytotoxic drugs. P-glycoprotein is an integral plasma membrane protein which contains 12 putative transmembrane regions and two ATP binding sites. It confers multidrug resistance by functioning as an energy-dependent drug efflux pump. Here we describe recent studies on the biosynthesis, structure, function, and mechanism of action of P-glycoprotein which have provided insights into the complexity of this multifunctional transport system and revealed an additional chloride channel activity. The physiological role of P-glycoprotein, however, still remains to be elucidated.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8095827     DOI: 10.1006/scel.1993.1008

Source DB:  PubMed          Journal:  Semin Cell Biol        ISSN: 1043-4682


  37 in total

1.  The role of Brugia malayi ATP-binding cassette (ABC) transporters in potentiating drug sensitivity.

Authors:  Jeffrey B Tompkins; Laurel E Stitt; Alana M Morrissette; Bernadette F Ardelli
Journal:  Parasitol Res       Date:  2011-04-15       Impact factor: 2.289

2.  Inhibition of multidrug resistance-associated protein (MRP) functional activity with pluronic block copolymers.

Authors:  D W Miller; E V Batrakova; A V Kabanov
Journal:  Pharm Res       Date:  1999-03       Impact factor: 4.200

3.  Mutual interactions between flavonoids and enzymatic and transporter elements responsible for flavonoid disposition via phase II metabolic pathways.

Authors:  Wen Jiang; Ming Hu
Journal:  RSC Adv       Date:  2012-09-21       Impact factor: 3.361

Review 4.  Molecular analysis of the multidrug transporter.

Authors:  U A Germann
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

5.  To use MIBI or not to use MIBI? That is the question when assessing tumour cells.

Authors:  Jean-Luc Moretti; Nathalie Hauet; Meltem Caglar; Olivier Rebillard; Zeynep Burak
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-07       Impact factor: 9.236

6.  Influence of cytokines on mdr1 expression in human colon carcinoma cell lines: increased cytotoxicity of MDR relevant drugs.

Authors:  W Walther; U Stein
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

Review 7.  Modulation of tumor cell gene expression and phenotype by the organ-specific metastatic environment.

Authors:  R Radinsky
Journal:  Cancer Metastasis Rev       Date:  1995-12       Impact factor: 9.264

8.  Both P-gp and MRP2 mediate transport of Lopinavir, a protease inhibitor.

Authors:  Sheetal Agarwal; Dhananjay Pal; Ashim K Mitra
Journal:  Int J Pharm       Date:  2007-03-06       Impact factor: 5.875

9.  Dissimilar invasive and metastatic behavior of vincristine and doxorubicin-resistant cell lines derived from a murine T cell lymphoid leukemia.

Authors:  Eloisi C Lopes; Glenda Ernst; Paula Aulicino; Silvia Vanzulli; Mariana García; Elida Alvarez; Silvia E Hajos
Journal:  Clin Exp Metastasis       Date:  2002       Impact factor: 5.150

10.  Human brain tumors: multidrug-resistance P-glycoprotein expression in tumor cells and intratumoral capillary endothelial cells.

Authors:  Silvia Fattori; Francesca Becherini; Maurizio Cianfriglia; Giuliano Parenti; Antonella Romanini; Maura Castagna
Journal:  Virchows Arch       Date:  2007-06-26       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.